Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monopar Therapeutics (MNPR) Equity Ratio (2016 - 2020)

Monopar Therapeutics (MNPR) has disclosed Equity Ratio for 5 consecutive years, with 0.96 as the latest value for Q3 2020.

  • Quarterly Equity Ratio rose 6.42% to 0.96 in Q3 2020 from the year-ago period, while the trailing twelve-month figure was 0.96 through Sep 2020, up 6.42% year-over-year, with the annual reading at 0.95 for FY2019, 0.04% changed from the prior year.
  • Equity Ratio hit 0.96 in Q3 2020 for Monopar Therapeutics, up from 0.95 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.98 in Q4 2016 to a low of 0.91 in Q3 2019.
  • Historically, Equity Ratio has averaged 0.95 across 5 years, with a median of 0.96 in 2018.
  • Biggest five-year swings in Equity Ratio: decreased 6.15% in 2019 and later rose 6.42% in 2020.
  • Year by year, Equity Ratio stood at 0.98 in 2016, then fell by 0.93% to 0.97 in 2017, then decreased by 2.39% to 0.95 in 2018, then increased by 0.04% to 0.95 in 2019, then grew by 1.87% to 0.96 in 2020.
  • Business Quant data shows Equity Ratio for MNPR at 0.96 in Q3 2020, 0.95 in Q2 2020, and 0.97 in Q1 2020.